(Q36968211)

17 August 2017

Does rosiglitazone increase cardiovascular outcomes? (English)

1 reference

17 August 2017

1 reference

Sheila A Doggrell

1

1 reference

PubMed ID

17931097

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

15

1 reference

17 August 2017

2665-2669

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Rosiglitazone--continued uncertainty about safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Rosiglitazone RECORD study: glucose control outcomes at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

Rosiglitazone and cardiotoxicity--weighing the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2665

10.1517/14656566.8.15.2665

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17931097